|
1
|
Louis DN, Ohgaki H, Wiestler OD, et al:
The 2007 WHO classification of tumours of the central nervous
system. Acta Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Normanno N, De Luca A, Bianco C, et al:
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene.
366:2–16. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torp SH, Helseth E, Dalen A and Unsgaard
G: Expression of epidermal growth factor receptor in human
meningiomas and meningeal tissue. APMIS. 100:797–802. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Smith JS, Lal A, Harmon-Smith M, Bollen AW
and McDermott MW: Association between absence of epidermal growth
factor receptor immunoreactivity and poor prognosis in patients
with atypical meningioma. J Neurosurg. 106:1034–1040. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wernicke AG, Dicker AP, Whiton M, et al:
Assessment of epidermal growth factor receptor (EGFR) expression in
human meningioma. Radiat Oncol. 5:462010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Carroll RS, Black PM, Zhang J, Kirsch M,
Percec I, Lau N and Guha A: Expression and activation of epidermal
growth factor receptors in meningiomas. J Neurosurg. 87:315–323.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mawrin C, Sasse T, Kirches E, et al:
Different activation of mitogen-activated protein kinase and Akt
signaling is associated with aggressive phenotype of human
meningiomas. Clin Cancer Res. 11:4074–4082. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kargiotis O, Chetty C, Gogineni V, et al:
uPA/uPAR downregulation inhibits radiation-induced migration,
invasion and angiogenesis in IOMM-Lee meningioma cells and
decreases tumor growth in vivo. Int J Oncol. 33:937–947.
2008.PubMed/NCBI
|
|
9
|
Johnson M and Toms S: Mitogenic signal
transduction pathways in meningiomas: novel targets for meningioma
chemotherapy? J Neuropathol Exp Neurol. 64:1029–1036. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Norden AD, Raizer JJ, Abrey LE, et al:
Phase II trials of erlotinib or gefitinib in patients with
recurrent meningioma. J Neurooncol. 96:211–217. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lynch TJ, Bell DW, Sordella R, et al:
Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non-small-cell lung cancer to
gefitinib. N Engl J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
De Roock W, Claes B, Bernasconi D, et al:
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy
of cetuximab plus chemotherapy in chemotherapy-refractory
metastatic colorectal cancer: a retrospective consortium analysis.
Lancet Oncol. 11:753–762. 2010.PubMed/NCBI
|
|
13
|
Brand TM, Iida M and Wheeler DL: Molecular
mechanisms of resistance to the EGFR monoclonal antibody cetuximab.
Cancer Biol Ther. 11:777–792. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Samuels Y, Wang Z, Bardelli A, et al: High
frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kosaka T, Yatabe Y, Endoh H, Kuwano H,
Takahashi T and Mitsudomi T: Mutations of the epidermal growth
factor receptor gene in lung cancer: biological and clinical
implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar
|
|
16
|
Diedrich U, Lucius J, Baron E, Behnke J,
Pabst B and Zoll B: Distribution of epidermal growth factor
receptor gene amplification in brain tumours and correlation to
prognosis. J Neurol. 242:683–688. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chaffanet M, Chauvin C, Lainé M, et al:
Comparative analysis of the NF2, TP53, PTEN, KRAS, NRAS and HRAS
genes in sporadic and radiation-induced human meningiomas. Int J
Cancer. 94:218–221. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schindler G, Capper D, Meyer J, et al:
Analysis of BRAF V600E mutation in 1,320 nervous system tumors
reveals high mutation frequencies in pleomorphic xanthoastrocytoma,
ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta
Neuropathol. 121:397–405. 2011. View Article : Google Scholar
|
|
19
|
Pang JC, Chung NY, Chan NH, Poon WS,
Thomas T and Ng HK: Rare mutation of PIK3CA in meningiomas. Acta
Neuropathol. 111:284–285. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bader AG, Kang S and Vogt PK:
Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc
Natl Acad Sci USA. 103:1475–1479. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Janku F, Wheler JJ, Naing A, et al: PIK3CA
mutation H1047R is associated with response to PI3K/AKT/mTOR
signaling pathway inhibitors in early-phase clinical trials. Cancer
Res. 73:276–284. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peters N, Wellenreuther R, Rollbrocker B,
Hayashi Y, Meyer-Puttlitz B, Duerr EM, Lenartz D, Marsh DJ, Schramm
J, Wiestler OD, Parsons R, Eng C and von Deimling A: Analysis of
the PTEN gene in human meningiomas. Neuropathol Appl Neurobiol.
24:3–8. 1998. View Article : Google Scholar
|
|
23
|
Willems L, Tamburini J, Chapuis N, Lacombe
C, Mayeux P and Bouscary D: PI3K and mTOR signaling pathways in
cancer: new data on targeted therapies. Curr Oncol Rep. 14:129–138.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Martini M, Ciraolo E, Gulluni F and Hirsch
E: Targeting PI3K in cancer: Any good news? Front Oncology.
3:1082013. View Article : Google Scholar : PubMed/NCBI
|
